Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):2331-2342. doi: 10.1111/jdv.18454. Epub 2022 Aug 23.
Our previous research revealed the relative local aggressiveness of eyelid and periocular squamous cell carcinoma (EPSCC), but its distinct genetic characteristics involved remain unknown.
We conducted this study based on next-generation sequencing to identify the genetic distinctiveness of EPSCC and damaging mutations for possible aetiology and poor prognosis.
We performed sequencing using a 556-gene panel (SmartOnco) in 48 EPSCCs. Cox hazards model was applied to explore mutated genes that increase the risk of metastasis and death. Pathogenesis of the mutations was predicted by sequence alignment algorithms.
The most commonly mutated genes were KMT2C (N = 17, 35%), LRP1B (N = 14, 29%), KMT2D (N = 12, 25%), PTCH1 (N = 10, 21%) and TP53 (N = 10, 21%). DNA mismatch repair (MMR) genes (42%) like MSH6 (19%) and MLH3 (12%) were among the most frequently mutated genes. Cell cycle regulators including TP53 (21%) and CDKN2A (10%) were less frequently mutated than in other squamous cell carcinomas (SCCs). Ultraviolet exposure, MMR deficiency and ageing were the main aetiology. Of note, KMT2C has a deleterious mutation hotspot. Patients burdened with MSH6 mutation has a higher risk of overall metastasis (P = 0.045, HR = 5.165) and nodal metastasis (P = 0.022, HR = 14.038). Moreover, a hotspot mutation MSH6 brought an even higher risk of nodal metastasis (P = 0.011, HR = 18.745).
EPSCCs displayed a unique mutation profile from cutaneous SCCs and mucosal SCCs. We have identified novel damaging mutations in epigenetic regulators like KMT2C boosted early onset of EPSCCs in addition to UVR, ageing or MMR deficiency. And malfunction of MMR genes worsened prognosis.
我们之前的研究揭示了眼睑和眶周鳞状细胞癌(EPSCC)的相对局部侵袭性,但涉及的独特遗传特征尚不清楚。
我们基于下一代测序进行这项研究,以确定 EPSCC 的遗传独特性以及可能的病因和不良预后的破坏性突变。
我们对 48 例 EPSCC 进行了 556 个基因面板(SmartOnco)测序。应用 Cox 风险模型来探索增加转移和死亡风险的突变基因。通过序列比对算法预测突变的发病机制。
最常见的突变基因是 KMT2C(N=17,35%)、LRP1B(N=14,29%)、KMT2D(N=12,25%)、PTCH1(N=10,21%)和 TP53(N=10,21%)。DNA 错配修复(MMR)基因(42%),如 MSH6(19%)和 MLH3(12%),是最常突变的基因之一。细胞周期调节剂,包括 TP53(21%)和 CDKN2A(10%),比其他鳞状细胞癌(SCC)的突变频率更低。紫外线暴露、MMR 缺陷和衰老为主要病因。值得注意的是,KMT2C 存在有害突变热点。携带 MSH6 突变的患者总体转移风险更高(P=0.045,HR=5.165)和淋巴结转移风险更高(P=0.022,HR=14.038)。此外,热点突变 MSH6 使淋巴结转移的风险更高(P=0.011,HR=18.745)。
EPSCC 显示出与皮肤 SCC 和黏膜 SCC 不同的独特突变谱。我们已经确定了表观遗传调节剂中的新型破坏性突变,如 KMT2C,除了 UVR、衰老或 MMR 缺陷外,还会导致 EPSCC 的早期发病。并且 MMR 基因的功能障碍会恶化预后。